Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
Launched by UNIVERSITY HOSPITAL, GRENOBLE · Mar 11, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well kidney and liver transplant patients respond to a booster vaccination for Hepatitis B (HBV). Because transplant patients take medications to suppress their immune system to help their new organ survive, they may not respond as strongly to vaccinations. The researchers want to see how effective the booster shot is in these patients and how different immune-suppressing medications might affect their response over a six-month period.
To be eligible for this trial, participants must be kidney or liver transplant recipients who are regularly followed up at the Grenoble University Hospital and are receiving specific medications called tacrolimus or belatacept. They should also have a clinical reason for needing the HBV booster vaccine. However, pregnant or breastfeeding women and those with a history of HBV infection cannot participate. If you join the study, you'll have your immune response carefully monitored, which involves checking your blood for specific antibodies and immune cells to see how well your body is responding to the vaccine.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Kidney or liver transplant recipients
- • Grenoble University Hospital regular follow-up
- • Tacrolimus or belatacept treated
- • Clinical indication for HBV booster vaccination
- Exclusion Criteria:
- • Pregnancy or lactating woman
- • History of HBV infection (either anti-Hepatitis B capside antigen (HBc), positivity or HBV-DNA positivity)
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grenoble, Aura, France
Patients applied
Trial Officials
Thomas JOUVE, MD, PhD
Principal Investigator
University Hospital, Grenoble
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported